Scarica l'app Stockscreener
25.65
2.22%
-0.5726
Precedente Chiudi:
$26.22
Aprire:
$26.25
Volume 24 ore:
438.11K
Relative Volume:
1.06
Capitalizzazione di mercato:
$900.51M
Reddito:
-
Utile/perdita netta:
$-74.31M
Rapporto P/E:
-10.33
EPS:
-2.4817
Flusso di cassa netto:
$-62.86M
1 W Prestazione:
-2.85%
1M Prestazione:
+40.40%
6M Prestazione:
+60.23%
1 anno Prestazione:
+1,024%
Intervallo 1D:
$24.30
$26.77
Intervallo di 1 settimana:
$24.30
$26.98
Portata 52W:
$2.29
$28.44
Alto Neuroscience Inc Stock (ANRO) Company Profile
Nome
Alto Neuroscience Inc
Settore
Industria
Telefono
773-255-5012
Indirizzo
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
25.66 | 920.16M | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
522.41 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.94 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.98 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.29 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.97 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-05 | Ripresa | Chardan Capital Markets | Buy |
| 2025-11-17 | Iniziato | BTIG Research | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-23 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-09-03 | Iniziato | Wedbush | Outperform |
| 2024-02-27 | Iniziato | Jefferies | Buy |
| 2024-02-27 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-27 | Iniziato | Stifel | Buy |
| 2024-02-27 | Iniziato | TD Cowen | Outperform |
| 2024-02-27 | Iniziato | William Blair | Outperform |
Mostra tutto
Alto Neuroscience Inc Borsa (ANRO) Ultime notizie
Alto Neuroscience (ANRO) Edges Lower as Shares Test Key Support ZoneEquity Put Call - dars.gov.et
ANROAlto Neuroscience Inc Latest SEC Filings - Finviz
Price to earnings forward of Alto Neuroscience, Inc. – NYSE:ANRO - TradingView
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - The National Law Review
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment? - Yahoo Finance
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider Loss Per Share on Higher R&D SpendingLow Estimate Range - dars.gov.et
Alto Neuroscience, Inc.(NYSE:ANRO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Alto Neuroscience, Inc.(NYSE: ANRO) added to Russell 3000E Growth Benchmark - marketscreener.com
Levi & Korsinsky Notifies Alto Neuroscience, Inc. (ANRO) Sharehol - The National Law Review
Investors SueWallSt as Alto Neuroscience, Inc. Faces Securities Fraud Allegations - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
ANRO Investors Have Opportunity to Lead Alto Neuroscience, Inc. C - The National Law Review
ANRO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
Alto Neuroscience, Inc. (ANRO) Class Action Lawsuit: Levi & Korsi - The National Law Review
H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO) - The Globe and Mail
Alto Neuroscience, Inc. Actuals & Estimates (BOATS:ANRO) - TradingView
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Alto Neuroscience Inc (ANRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point - Stocktwits
Alto Neuroscience Inc (ANRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Top Alto Neuroscience (ANRO) Competitors 2026 - MarketBeat
Alto Neuroscience Inc (ANRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alto Neuroscience Inc (ANRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alto Neuroscience Inc (ANRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alto Neuroscience Inc (ANRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alto Neuroscience Inc (ANRO) Institutional Confidence - TradingKey
Alto Neuroscience Inc (ANRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ANRO Q1 2026 Earnings: Wider-Than-Expected Loss Per Share Amid Clinical ProgressEarnings Analysis - dars.gov.et
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia - Weekly Voice
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineRevenue Beat Analysis - newsline.com
ANRO Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentEarnings Cycle Outlook - newsline.com
ANRO: Three late-stage psychiatry programs expect pivotal data readouts in 2027 - TradingView
Alto Neuroscience (ANRO) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Alto Neuroscience (ANRO) Edges Lower as Stock Hovers Near Key Support ZoneIndex Put Call - The Legal Advocate
Alto Neuroscience (ANRO) director awarded 26,000 stock options at $20.44 strike price - Stock Titan
Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3 - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board of Directors - geneonline.com
Alto Neuroscience, Inc. (ANRO) Files 8-K Report Announcing No Soliciting Material or Tender Offers – Company Info & NYSE Listing - Minichart
Alto Neuroscience appoints Andrew Miller to board of directors By Investing.com - Investing.com South Africa
Alto Neuroscience appoints Andrew Miller to board of directors - Investing.com
Biotech leader Andrew Miller joins Alto Neuroscience (ANRO) board and governance committee - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Australia
Alto Neuroscience Inc Azioni (ANRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
3.14%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):